Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 68Gastrointestinal 20Thoracic 13Tumor-Agnostic 12CNS 8Gynecologic 7Dermatologic 7Other solid neoplasm 6Sarcoma 5Head & Neck 5Endocrine 4Other hematologic neoplasm 2Breast 2Plasma cell 1NET 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 2Ovarian Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Axitinib × Breast × Clear all
NCT05904730 2024-12-30

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Lynkcell Europe

Phase 1 Completed
10 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT00076024 2012-06-26

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Pfizer

Phase 1/2 Completed
174 enrolled 14 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡